First published 10/3/2026, 12:55:15 AM · Last updated 10/3/2026, 12:55:15 AM

MA11.04 Safety of Lurbinectedin + Atezolizumab as 1L Maintenance Treatment in ES-SCLC: Results From the Phase 3 IMforte Study

A journal article reporting safety results for the combination of lurbinectedin and atezolizumab as first-line maintenance treatment for extensive-stage small-cell lung cancer from the Phase 3 IMforte study. The supplied record includes only the article title, publisher, and content type without outcome details.

Illustrative image: Radiologic evidence of tumor responses to lurbi (lurbinectedin) — Moussa MJ, Khandelwal J, Wilson NR, Naik SA, Subbiah V, Campbell MT, Msaouel P, Singh P, Alhalabi O./Wikimedia Commons, CC BY 4.0

Categories: public-health, science-and-space

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 3/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 5/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 3/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

Contains clinical safety data on a first-line maintenance therapy combination for extensive-stage small-cell lung cancer.

Sources

MA11.04 Safety of Lurbinectedin + Atezolizumab as 1L Maintenance Treatment in ES-SCLC: Results From the Phase 3 IMforte Study

Report an issue